See more
How has ERBA Diagnostics' stock performed in 2022?
ERBA Diagnostics' stock was trading at $0.0350 at the beginning of 2022. Since then, ERBA shares have increased by 0.0% and is now trading at $0.03...
Who are ERBA Diagnostics' key executives?
ERBA Diagnostics' management team includes the following people: Mr. Suresh Vazirani , Exec. Chairman & MD (Age 69) Mr. David Barka , Interim C...
Who are some of ERBA Diagnostics' key competitors?
Some companies that are related to ERBA Diagnostics include Abliva AB (publ) (NEVPF) , Acusphere (ACUS) , ADC Therapeutics (ADCT) , Addex Thera...
What other stocks do shareholders of ERBA Diagnostics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other ERBA Diagnostics investors own include EKF Diagnostics (EK...
What is ERBA Diagnostics' stock symbol?
ERBA Diagnostics trades on the OTCMKTS under the ticker symbol "ERBA."
How do I buy shares of ERBA Diagnostics?
Shares of ERBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBul...
What is ERBA Diagnostics' stock price today?
One share of ERBA stock can currently be purchased for approximately $0.04.
What is ERBA Diagnostics' official website?
The official website for ERBA Diagnostics is www.erbadiagnostics.com .
How can I contact ERBA Diagnostics?
ERBA Diagnostics' mailing address is 14100 Nw 57th Court, Miami Lakes FL, 33014 . The company can be reached via phone at 305-324-2300 , via emai...
Who makes Erba test kits?
ERBA Diagnostics, In c. develops, manufactures and markets diagnostic test kits, or assays, and automated systems primarily for autoimmune and infectious diseases. The main subsidiaries of the company include: Diamedix Corporation, Delta Biologicals S.r.l. and ImmunoVision, Inc. ERBA Diagnostics, Inc., formerly known as IVAX Diagnostics, Inc., is headquartered in Miami, Florida.
What is Zacks ESP?
Zacks Earnings ESP (Expected Surprise Prediction ) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.
